Editor’s note: This is a developing news story. Please check back soon for updates.
Alcon will acquire LumiThera, including its photobiomodulation device for early and intermediate dry age-related macular degeneration, according to a press release.
The photobiomodulation (PBM) device, known as the Valeda light delivery system, uses non-phototoxic light therapy to stimulate mitochondrial energy production in the retina. It demonstrated positive results in the pivotal LIGHTSITE III study, which compared the treatment with control light therapy for 2 years.
The FDA granted de novo marketing